Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravascular coagulation. 2. Underlying conditions and therapy

H R Gralnick

    Postgraduate Medicine
    |November 1, 1977
    PubMed
    Summary

    Treatment for intravascular coagulation focuses on the root cause. For active bleeding or uncorrectable disorders, intravenous heparin anticoagulation is crucial, often combined with platelet transfusions for thrombocytopenia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Conformational regulation of the fibronectin binding and alpha 3beta 1 integrin-mediated adhesive activities of thrombospondin-1.

    The Journal of biological chemistry·2001
    Same author

    Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17).

    Leukemia·2000
    Same author

    Plasma glycocalicin in platelet concentrates: relationship to other parameters of the storage lesion.

    Thrombosis research·1998
    Same author

    Glycocalicin levels in the plasma of HIV+ patients: an indicator of platelet turnover.

    The Journal of laboratory and clinical medicine·1998
    Same author

    Platelet von Willebrand factor in Hermansky-Pudlak syndrome.

    American journal of hematology·1998
    Same author

    Structure-function studies on the inhibition of binding of alpha-thrombin to platelet GpIb alpha by the peptide D-Y-Y-P-E and the artifactual inhibitory activity of C-terminal E in this peptide.

    Thrombosis research·1998

    Area of Science:

    • Hematology
    • Internal Medicine
    • Critical Care Medicine

    Background:

    • Intravascular coagulation requires prompt and targeted therapeutic interventions.
    • Management strategies must address both the underlying cause and active clinical manifestations.

    Purpose of the Study:

    • To outline the therapeutic approaches for intravascular coagulation.
    • To define the indications for anticoagulation and supportive measures.

    Main Methods:

    • Review of current treatment guidelines for intravascular coagulation.
    • Emphasis on heparin anticoagulation for active bleeding or uncorrectable disorders.
    • Inclusion of platelet transfusions when thrombocytopenia is present.

    Main Results:

    • Therapy is primarily directed at the underlying disorder.
    • Heparin anticoagulation is indicated for active bleeding or uncorrectable conditions.
    • Platelet transfusion is essential when thrombocytopenia accompanies heparinization.

    Conclusions:

    • Effective management of intravascular coagulation involves addressing the primary condition and employing anticoagulation with heparin when necessary.
    • Monitoring therapeutic efficacy through cessation of bleeding, thrombosis resolution, and normalization of coagulation factors is critical.
    • Coagulation factor levels, especially factor V and fibrinogen, serve as key indicators of treatment success.

    Related Experiment Videos